Pub. Date : 2005 Mar
PMID : 15608135
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Selective inhibition of human cytochrome P4502C8 by montelukast. | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 2 | The leukotriene receptor antagonist montelukast was examined for its inhibition of the human drug-metabolizing enzyme cytochrome P4502C8 (CYP2C8). | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 3 | The leukotriene receptor antagonist montelukast was examined for its inhibition of the human drug-metabolizing enzyme cytochrome P4502C8 (CYP2C8). | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 4 | Montelukast was demonstrated to be a potent inhibitor of CYP2C8-catalyzed amodiaquine N-deethylase, rosiglitazone N-demethylase, and paclitaxel 6alpha-hydroxylase in human liver microsomes. | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 5 | Montelukast was a selective inhibitor for human CYP2C8; inhibition of other human cytochrome P450 enzymes was substantially less. | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 6 | These in vitro data support the use of montelukast as a selective CYP2C8 inhibitor that could be used to determine the contribution of this enzyme to drug metabolism reactions. | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 7 | These data also raise the possibility that montelukast could have an effect on the metabolic clearance of drugs possessing CYP2C8-catalyzed metabolism as a major clearance pathway, thereby eliciting pharmacokinetic drug-drug interactions. | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |